Transcriptome analysis of VCaP xenografts resistant to dual therapy with abiraterone and enzalutamide

We report RNA sequencing data on serial biopsies of prostate cancer VCaP xenografts as the tumors pass from androgen-sensitivity (Pre-Cx), to castration resistance (CRPC, castration resistant prostate cancer), onto resistance to dual therapy with abiraterone plus enzalutamide (AER). From comparison of these RNAseq data sets, we were able to determine differentially expressed genes between the AER/CRPC and Pre-Cx states that could mediate resistance to androgen deprivation therapies. RNA sequencing of the transcriptome of serial biopsies (Pre-Cx, CRPC, and Abi/Enza resistant) of 4 VCaP xenograft tumors.